Felipe Villacampa

Dr. Felipe Villacampa

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 November 2017 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
VMVíctor G MARTINEZ
Víctor G MARTINEZ
CRCarolina Rubio
Carolina Rubio
MMMónica Martínez-Fernández
Mónica Martínez-Fernández
CSCristina Segovia
Cristina Segovia
FLFernando López-Calderón
Fernando López-Calderón
MDMarta Dueñas
Marta Dueñas
Purpose: Bladder cancer is a current clinical and social problem. At diagnosis, most patients present with nonmuscle-invasive tumors, characterized by a high recurrence rate, which could progress to muscle-invasive disease and metastasis. Bone morphogenetic protein (BMP)–dependent signaling arising from stromal bladder tissue mediates urothelial homeostasis by promoting urothelial cell differentiation. However, the possible role of BMP ligands in bladder cancer is still unclear. Experimental Design: Tumor and normal tissue from 68 patients with urothelial cancer were prospectively collected and analyzed for expression of BMP and macrophage markers. The mechanism of action was assessed in vitro by experiments with bladder cancer cell lines and peripheral blood monocyte–derived macrophages. Results: We observed BMP4 expression is associated and favored type II macrophage differentiation. In vitro experiments showed that both recombinant BMP4 and BMP4-containing conditioned media from bladder cancer cell lines favored monocyte/macrophage polarization toward M2 phenotype macrophages, as shown by the expression and secretion of IL10. Using a series of human bladder cancer patient samples, we also observed increased expression of BMP4 in advanced and undifferentiated tumors in close correlation with epithelial–mesenchymal transition (EMT). However, the p-Smad 1,5,8 staining in tumors showing EMT signs was reduced, due to the increased miR-21 expression leading to reduced BMPR2 expression. Conclusions: These findings suggest that BMP4 secretion by bladder cancer cells provides the M2 signal necessary for a protumoral immune environment. In addition, the repression of BMPR2 by miR-21 makes the tumor cells refractory to the prodifferentiating actions mediated by BMP ligands, favoring tumor growth. Clin Cancer Res; 23(23); 7388–99. ©2017 AACR.

3 July 2019 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
CSCristina Segovia
Cristina Segovia
EJEdurne San José
Edurne San José
EMEster Munera-Maravilla
Ester Munera-Maravilla
MMMónica Martínez-Fernández
Mónica Martínez-Fernández
LGLeire Garate
Leire Garate
JESÚS M ParamioJESÚS M Paramio
JESÚS M Paramio

31 January 2017 in Clinical Epigenetics
Verified
Journal Article
Open access
PDF file
AFAndrew Feber
Andrew Feber
PDPawan Dhami
Pawan Dhami
LDLiqin Dong
Liqin Dong
PWPatricia de Winter
Patricia de Winter
WTWei Shen Tan
Wei Shen Tan
JKJohn D. Kelly
John D. Kelly
Bladder cancer (BC) is one of the most common cancers in the western world and ranks as the most expensive to manage, due to the need for cystoscopic examination. BC shows frequent changes in DNA methylation, and several studies have shown the potential utility of urinary biomarkers by detecting epigenetic alterations in voided urine. The aim of this study is to develop a targeted bisulfite next-generation sequencing assay to diagnose BC from urine with high sensitivity and specificity. We defined a 150 CpG loci biomarker panel from a cohort of 86 muscle-invasive bladder cancers and 30 normal urothelium. Based on this panel, we developed the UroMark assay, a next-generation bisulphite sequencing assay and analysis pipeline for the detection of bladder cancer from urinary sediment DNA. The 150 loci UroMark assay was validated in an independent cohort (n = 274, non-cancer (n = 167) and bladder cancer (n = 107)) voided urine samples with an AUC of 97%. The UroMark classifier sensitivity of 98%, specificity of 97% and NPV of 97% for the detection of primary BC was compared to non-BC urine. Epigenetic urinary biomarkers for detection of BC have the potential to revolutionise the management of this disease. In this proof of concept study, we show the development and utility of a novel high-throughput, next-generation sequencing-based biomarker for the detection of BC-specific epigenetic alterations in urine.

13 November 2014 in Cancer Research
Verified
Journal Article
Closed access
PDF file
MSMirentxu Santos
Mirentxu Santos
MMMónica Martínez-Fernández
Mónica Martínez-Fernández
MDMarta Dueñas
Marta Dueñas
RGRamon Garcia-Escudero
Ramon Garcia-Escudero
BABegoña Alfaya
Begoña Alfaya
JESÚS M ParamioJESÚS M Paramio
JESÚS M Paramio
Bladder cancer is a highly prevalent human disease in which retinoblastoma (Rb) pathway inactivation and epigenetic alterations are common events. However, the connection between these two processes is still poorly understood. Here, we show that the in vivo inactivation of all Rb family genes in the mouse urothelium is sufficient to initiate bladder cancer development. The characterization of the mouse tumors revealed multiple molecular features of human bladder cancer, including the activation of E2F transcription factor and subsequent Ezh2 expression and the activation of several signaling pathways previously identified as highly relevant in urothelial tumors. These mice represent a genetically defined model for human high-grade superficial bladder cancer. Whole transcriptional characterizations of mouse and human bladder tumors revealed a significant overlap and confirmed the predominant role for Ezh2 in the downregulation of gene expression programs. Importantly, the increased tumor recurrence and progression in human patients with superficial bladder cancer is associated with increased E2F and Ezh2 expression and Ezh2-mediated gene expression repression. Collectively, our studies provide a genetically defined model for human high-grade superficial bladder cancer and demonstrate the existence of an Rb–E2F–Ezh2 axis in bladder whose disruption can promote tumor development. Cancer Res; 74(22); 6565–77. ©2014 AACR.

1 January 2019 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
CRCarolina Rubio
Carolina Rubio
MMMónica Martínez-Fernández
Mónica Martínez-Fernández
CSCristina Segovia
Cristina Segovia
ILIris Lodewijk
Iris Lodewijk
CSCristian Suárez-Cabrera
Cristian Suárez-Cabrera
JESÚS M ParamioJESÚS M Paramio
JESÚS M Paramio
Purpose: Bladder cancer (BC) is a clinical and social problem due to its high incidence and recurrence rates. It frequently appears in elderly patients showing other medical comorbidities that hamper the use of standard chemotherapy. We evaluated the activity of CDK4/6 inhibitor as a new therapy for patients unfit for cisplatin (CDDP). Experimental Design: BC cell lines were tested for in vitro sensitivity to CDK4/6 inhibition. A novel metastatic BC mouse model was developed and used to test its in vivo activity. Results: Cell lines tested were sensitive to CDK4/6 inhibition, independent on RB1 gene status. Transcriptome analyses and knockdown experiments revealed a major role for FOXM1 in this response. CDK4/6 inhibition resulted in reduced FOXM1 phosphorylation in vitro and in vivo and showed synergy with CDDP, allowing a significant tumor regression. FOXM1 exert important oncogenic roles in BC. Conclusions: CDK4/6 inhibitors, alone or in combination, are a novel therapeutic strategy for advanced BC patients previously classified as unfit for current treatment options.

8 October 2015 in Clinical Epigenetics
Verified
Journal Article
Open access
PDF file
MMMonica Martinez-Fernandez
Monica Martinez-Fernandez
AFAndrew Feber
Andrew Feber
MDMarta Dueñas
Marta Dueñas
CACristina Segovia de Andrés
Cristina Segovia de Andrés
CRCarolina Rubio
Carolina Rubio
JESÚS M ParamioJESÚS M Paramio
JESÚS M Paramio
Long non-coding RNAs (lncRNAs) have been claimed as key molecular players in gene expression regulation, being involved in diverse epigenetic processes. They are aberrantly expressed in various tumors, but their exact role in bladder cancer is still obscure. We have recently found a major role of the Polycomb repression complex in recurrence of non-muscle-invasive bladder cancer. Here, we report the xpression of Polycomb-related lncRNAs:antisense noncoding RNA in the INK4 locus (ANRIL) and HOX antisense intergenic RNA (HOTAIR) in these tumors. We studied a dataset of non-invasive bladder cancer samples by quantitative reverse transcription PCR (RT-qPCR) and analyzed also invasive bladder cancer samples using TCGA data. Our results showed that, while ANRIL seemed not to have a determining role, an increased HOTAIR expression appeared in recurrent and high-graded tumors associated with poor prognosis. In addition, through genome-wide transcriptome analyses, we observed that HOTAIR-EZH2-complex-regulated genes can efficiently discriminate between non-tumoral, recurrent, and non-recurrent bladder cancer samples. We also observed a significant correlation between EZH2 and HOTAIR expression levels. Using overexpression, knockdown, and pharmacological approaches in bladder cancer cell lines, we also observed that EZH2 regulates HOTAIR expression. Our findings indicate that HOTAIR expression has prognostic value for bladder cancer progression, recurrence, and survival and suggest that HOTAIR plays active roles in modulating the cancer epigenome, becoming an interesting candidate as a target for cancer diagnosis and therapy. The observed HOTAIR regulation by EZH2 and the possibility of modulating EZH2 activity with specific inhibitors open new possible paths to be explored in bladder cancer therapy.